ICU Medical CFO Brian Bonnell Sells 9,307 Shares
Key Points
The transaction involved shares equal to 13% of the stake held before the filing.
The disposition was a direct sell of common stock, and the reporting person retains no indirect equity holdings.
The sale was executed under a Rule 10b5-1 trading plan adopted by the executive on June 1, 2026.
Chief Financial Officer Brian Michael Bonnell executed a sale of 9,307 shares of ICU Medical (NASDAQ:ICUI) on Aug. 31, 2026, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $1.6 million |
| Shares sold | 9,307 |
| Post-transaction shares (directly held) | 62,443 |
| Post-transaction value | $10.8 million |
Transaction value based on SEC Form 4 weighted average sale price ($172.79); post-transaction value based on Aug. 31, 2026, market close ($172.95).
Key questions
- What was the nature of the execution?
The sale was conducted through multiple transactions at prices ranging from $170.57 to $174.08 per share. This activity was scheduled under a Rule 10b5-1 trading plan, a mechanism that allows insiders to set up a pre-determined schedule for selling stock to avoid concerns about trading on non-public information. - What is the scale of the remaining equity position?
Following this transaction, Bonnell holds 62,443 direct shares in the medical technology firm. The position was valued at $10.8 million, representing approximately 0.2% of the total company. - How has the stock performed leading up to this filing?
The stock has experienced a 35% return over the one-period ending on the Aug. 31, 2026.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-28) | $175.10 |
| Market Capitalization | $3.8 billion |
| Revenue (TTM) | $2.2 billion |
| Net Income (TTM) | $30.1 million |
Company Snapshot
- ICU Medical develops, manufactures, and sells medical devices for infusion therapy and critical care applications, including needle-free connectors, catheter maintenance solutions, and hemodialysis products that generate the majority of the company's revenue.
- The company operates a global manufacturing and distribution business model, leveraging proprietary technology platforms to deliver specialized medical devices to healthcare providers and hospitals seeking to improve patient safety and clinical outcomes.
- The company operates a global manufacturing and distribution business model, leveraging proprietary technology platforms to deliver specialized medical devices to healthcare providers and hospitals seeking to improve patient safety and clinical outcomes.
- ICU Medical primarily serves hospitals, dialysis centers, and healthcare systems that require infusion therapy and critical care solutions, with customers spanning both domestic and international markets.
ICU Medical is a global medical technology company with approximately 13,000 employees and a market capitalization of $3.8 billion, generating $2.2 billion in TTM revenue. The company maintains a focused strategy in the infusion therapy and critical care markets, leveraging proprietary connector and disinfection technologies to achieve competitive differentiation and support recurring revenue streams from healthcare provider customers worldwide.
What this transaction means for investors
On Aug. 31, Bonnell sold shares in multiple transactions, totaling 9,307 shares. Digging into the details, this doesn't appear to offer any cause for concern for shareholders. This sale was part of a plan already established in June 2026. That means this wasn't a spur-of-the-moment decision, which helps to validate that the sale isn't a signal that something may be amiss with ICU Medical. Also, although Bonnell sold approximately 9,300 shares, he still holds over 62,000 shares. That shows deep and sustained alignment with the company's success. And finally, based on ICU Medical's stock price performance over the past 12 months, shareholders shouldn't be overly worried. Over the past year, shares of ICU Medical are up 19.3%, while the S&P 500 is up 14.3%.
For what could be ahead for the company over the next 12 months, analysts are generally bullish. Of the eight who cover the stock, 88% rate it a buy, while 13% rate it a hold. From that group, the median one-year price target is $195, representing a potential 25.3% gain from today's price ($155.62).
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.